Eris Lifesciences Ltd (IN:ERIS)
:ERIS
ERIS Stock Chart & Stats
₹1530.85
₹7.70(0.59%)
At close: 4:00 PM EST
₹1530.85
₹7.70(0.59%)
Day’s Range― - ―
52-Week Range₹1,187.10 - ₹1,909.55
Previous CloseN/A
Volume91.31K
Average Volume (3M)2.07K
Market Cap
₹181.72B
Enterprise Value₹207.88B
Total Cash (Recent Filing)₹839.20M
Total Debt (Recent Filing)₹23.89B
Price to Earnings (P/E)51.4
Beta0.58
Next Earnings
May 26, 2026EPS Estimate
11.7Next Dividend Ex-DateN/A
Dividend Yield0.47%
Share Statistics
EPS (TTM)7.30
Shares Outstanding138,542,900
10 Day Avg. Volume1,915
30 Day Avg. Volume2,071
Financial Highlights & Ratios
PEG Ratio-5.23
Price to Book (P/B)6.64
Price to Sales (P/S)6.58
P/FCF Ratio20.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)52.26
Revenue Forecast (FY)₹37.31B
Bulls Say, Bears Say
Bulls Say
Recurring Revenue From Chronic Branded FormulationsEris’s focus on branded formulations for chronic and lifestyle diseases creates recurring revenue from long-duration prescriptions. Combined with a dedicated physician-facing sales network, this model supports predictable demand, higher brand loyalty and durable revenue visibility over multiple quarters.
Strong Revenue And Operating Cash Flow GrowthReported strong revenue and operating cash flow growth indicates the business converts sales into cash effectively. Durable cash generation improves the company’s ability to reinvest in brands, fund working capital, and pursue bolt-on acquisitions without relying heavily on external financing.
Robust Margins And Operational EfficiencyConsistently strong gross and EBITDA margins signal effective cost management and pricing power in core brands. Sustained margin strength allows room for continued brand investment and protects profitability against moderate volume swings or rising marketing costs.
Bears Say
Free Cash Flow VolatilityAlthough operating cash flow has grown, Free Cash Flow shows notable fluctuations. Persistent FCF volatility can limit strategic flexibility, constrain sizable M&A or capex plans, and increase sensitivity to working-capital swings or one-time cash demands over the next several quarters.
High Marketing And Sales-force Driven Cost BaseReliance on an extensive field force and brand-promotion spending is structurally costly. If brand uptake slows or competitive intensity increases, margin pressure can persist because fixed and recurring promotional expenses are hard to scale down quickly without losing prescriber traction.
Concentration In Indian Domestic Market And Price-control ExposureHeavy reliance on the Indian market concentrates regulatory and pricing risk: any adverse price-control actions or policy changes could directly compress revenue and margins. Limited geographic diversification reduces buffers against domestic demand shocks or regulatory shifts.
Eris Lifesciences Ltd News
ERIS FAQ
What was Eris Lifesciences Ltd’s price range in the past 12 months?
Eris Lifesciences Ltd lowest stock price was ₹1187.10 and its highest was ₹1909.55 in the past 12 months.
What is Eris Lifesciences Ltd’s market cap?
Eris Lifesciences Ltd’s market cap is ₹181.72B.
When is Eris Lifesciences Ltd’s upcoming earnings report date?
Eris Lifesciences Ltd’s upcoming earnings report date is May 26, 2026 which is in 53 days.
How were Eris Lifesciences Ltd’s earnings last quarter?
Eris Lifesciences Ltd released its earnings results on Feb 13, 2026. The company reported ₹7.3 earnings per share for the quarter, missing the consensus estimate of ₹9.625 by -₹2.325.
Is Eris Lifesciences Ltd overvalued?
According to Wall Street analysts Eris Lifesciences Ltd’s price is currently Overvalued.
Does Eris Lifesciences Ltd pay dividends?
Eris Lifesciences Ltd pays a Annually dividend of ₹7.35 which represents an annual dividend yield of 0.47%. See more information on Eris Lifesciences Ltd dividends here
What is Eris Lifesciences Ltd’s EPS estimate?
Eris Lifesciences Ltd’s EPS estimate is 11.7.
How many shares outstanding does Eris Lifesciences Ltd have?
Eris Lifesciences Ltd has 138,542,900 shares outstanding.
What happened to Eris Lifesciences Ltd’s price movement after its last earnings report?
Eris Lifesciences Ltd reported an EPS of ₹7.3 in its last earnings report, missing expectations of ₹9.625. Following the earnings report the stock price went down -6.38%.
Which hedge fund is a major shareholder of Eris Lifesciences Ltd?
Currently, no hedge funds are holding shares in IN:ERIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eris Lifesciences Ltd
Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, antidiabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, respiratory, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, as well as in-vitro fertilization, cosmetology, and dermatology. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.
Technical Analysis
Emcure Pharmaceuticals Limited
―
Gland Pharma Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
Sanofi Consumer Healthcare India Limited
―